Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616912 · ClinicalTrials.gov registry record · Phase 3
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 830
- Enrollment target
NCT03616912 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 830 participants.
The verdict
NCT03616912, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 830 participants
- Enrollment target
Study Summary
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03616912
The ClinicalTrials.gov registry entry for NCT03616912 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 830 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03616912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03616912 about?
NCT03616912 is a clinical study titled "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus". The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
What is the current status of trial NCT03616912?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 830 participants. The study started on 2018-08-02. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT03616912?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT03616912?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.